Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

The use of Trichomonas vaginalis purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors.

Parker WB, Allan PW, Waud WR, Hong J, Gilbert-Ross M, Achyut BR, Joshi D, Behbahani T, Rab R, Ealick SE, Sorscher EJ.

Cancer Chemother Pharmacol. 2020 Jan 8. doi: 10.1007/s00280-019-04018-7. [Epub ahead of print]

PMID:
31915968
2.

Thiarabine, 1-(4-Thio-β-D-arabinofuranosyl)cytosine. A Deoxycytidine Analog With Excellent Anticancer Activity.

Parker WB, Waud WR, Secrist JA 3rd.

Curr Med Chem. 2015;22(34):3881-96. Review.

PMID:
26597061
3.

Preclinical combination therapy of clofarabine plus radiation.

Stackhouse MA, Gilbert KS, Scoggins JW, Waud WR.

Nucleosides Nucleotides Nucleic Acids. 2012;31(9):692-705.

PMID:
23004932
4.

Preclinical antitumor activity of thiarabine in human leukemia and lymphoma xenograft models.

Waud WR, Gilbert KS, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2012;31(9):647-60.

PMID:
23004929
5.

Preclinical combination therapy of thiarabine plus various clinical anticancer agents.

Waud WR, Gilbert KS, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2012;31(8):630-46. doi: 10.1080/15257770.2012.712181.

PMID:
22908953
6.

In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.

Sorscher EJ, Hong JS, Allan PW, Waud WR, Parker WB.

Cancer Chemother Pharmacol. 2012 Aug;70(2):321-9. doi: 10.1007/s00280-012-1908-9. Epub 2012 Jul 4.

7.

Isolation and characterization of a murine P388 leukemia line resistant to thiarabine.

Waud WR, Parker WB, Gilbert KS, Secrist JA.

Nucleosides Nucleotides Nucleic Acids. 2012;31(1):14-27. doi: 10.1080/15257770.2011.637099.

PMID:
22257207
8.

Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.

Lu W, Lin C, Roberts MJ, Waud WR, Piazza GA, Li Y.

PLoS One. 2011;6(12):e29290. doi: 10.1371/journal.pone.0029290. Epub 2011 Dec 16.

9.

Synthesis and evaluation of the substrate activity of C-6 substituted purine ribosides with E. coli purine nucleoside phosphorylase: palladium mediated cross-coupling of organozinc halides with 6-chloropurine nucleosides.

Hassan AE, Abou-Elkhair RA, Riordan JM, Allan PW, Parker WB, Khare R, Waud WR, Montgomery JA, Secrist JA 3rd.

Eur J Med Chem. 2012 Jan;47(1):167-74. doi: 10.1016/j.ejmech.2011.10.039. Epub 2011 Nov 4.

10.

Isolation and characterization of a murine P388 leukemia line resistant to clofarabine.

Waud WR, Gilbert KS, Parker WB, Secrist JA.

Nucleosides Nucleotides Nucleic Acids. 2011 Nov;30(11):826-38. doi: 10.1080/15257770.2011.604662.

PMID:
22060549
11.

Mesd is a general inhibitor of different Wnt ligands in Wnt/LRP signaling and inhibits PC-3 tumor growth in vivo.

Lin C, Lu W, Zhai L, Bethea T, Berry K, Qu Z, Waud WR, Li Y.

FEBS Lett. 2011 Oct 3;585(19):3120-5. doi: 10.1016/j.febslet.2011.08.046. Epub 2011 Sep 5.

12.

Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase.

Parker WB, Allan PW, Waud WR, Hong JS, Sorscher EJ.

Cancer Gene Ther. 2011 Jun;18(6):390-8. doi: 10.1038/cgt.2011.4. Epub 2011 Mar 11.

13.

Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies.

Bertino JR, Waud WR, Parker WB, Lubin M.

Cancer Biol Ther. 2011 Apr 1;11(7):627-32. Epub 2011 Apr 1. Review.

14.

Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.

Waud WR, Gilbert KS, Secrist JA 3rd.

Cancer Chemother Pharmacol. 2011 Aug;68(2):399-403. doi: 10.1007/s00280-010-1498-3. Epub 2010 Nov 11.

15.

BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors.

Adams DJ, Waud WR, Wani MC, Manikumar G, Flowers JL, Driscoll TA, Morgan LR.

Cancer Chemother Pharmacol. 2011 Apr;67(4):855-65. doi: 10.1007/s00280-010-1388-8. Epub 2010 Jun 22.

16.

Synthesis and anticancer evaluation of 4'-C-methyl-2'-fluoro arabino nucleosides.

Tiwari KN, Shortnacy-Fowler AT, Parker WB, Waud WR, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2009 May;28(5):657-77. doi: 10.1080/15257770903091946.

PMID:
20183608
17.

Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents.

Morgan LR, Struck RF, Waud WR, LeBlanc B, Rodgers AH, Jursic BS.

Cancer Chemother Pharmacol. 2009 Sep;64(4):829-35. doi: 10.1007/s00280-009-0933-9. Epub 2009 Mar 3.

18.

Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine.

Parker WB, Shaddix SC, Gilbert KS, Shepherd RV, Waud WR.

Cancer Chemother Pharmacol. 2009 Jul;64(2):253-61. doi: 10.1007/s00280-008-0862-z. Epub 2008 Nov 11.

PMID:
19002461
19.

In silico chemical library screening and experimental validation of a novel 9-aminoacridine based lead-inhibitor of human S-adenosylmethionine decarboxylase.

Brooks WH, McCloskey DE, Daniel KG, Ealick SE, Secrist JA 3rd, Waud WR, Pegg AE, Guida WC.

J Chem Inf Model. 2007 Sep-Oct;47(5):1897-905. Epub 2007 Aug 4.

PMID:
17676832
20.

Novel boron-containing, nonclassical antifolates: synthesis and preliminary biological and structural evaluation.

Reynolds RC, Campbell SR, Fairchild RG, Kisliuk RL, Micca PL, Queener SF, Riordan JM, Sedwick WD, Waud WR, Leung AK, Dixon RW, Suling WJ, Borhani DW.

J Med Chem. 2007 Jul 12;50(14):3283-9. Epub 2007 Jun 15.

PMID:
17569517
21.

The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.

Goldsmith ME, Aguila A, Steadman K, Martinez A, Steinberg SM, Alley MC, Waud WR, Bates SE, Fojo T.

Mol Cancer Ther. 2007 Feb;6(2):496-505.

22.

Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.

Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, Waud WR, Zhang X.

Cancer Chemother Pharmacol. 2007 Feb;59(2):183-95. Epub 2006 May 25.

PMID:
16724239
23.

Design and evaluation of 5'-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant.

Parker WB, Allan PW, Ealick SE, Sorscher EJ, Hassan AE, Silamkoti AV, Fowler AT, Waud WR, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2005;24(5-7):387-92.

PMID:
16247956
24.
25.

Thiolo-, thiono- and dithiocarbonate and thiocarbamate derivatives of demethylpenclomedine as novel anticancer agents.

Struck RF, Waud WR.

Cancer Chemother Pharmacol. 2006 Jan;57(2):180-4. Epub 2005 Aug 11.

PMID:
16096790
26.

Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850).

Straub JA, Chickering DE, Lovely JC, Zhang H, Shah B, Waud WR, Bernstein H.

Pharm Res. 2005 Mar;22(3):347-55.

PMID:
15835739
27.

Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy.

Bharara S, Sorscher EJ, Gillespie GY, Lindsey JR, Hong JS, Curlee KV, Allan PW, Gadi VK, Alexander SA, Secrist JA 3rd, Parker WB, Waud WR.

Hum Gene Ther. 2005 Mar;16(3):339-47.

PMID:
15812229
28.

Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide.

Germann N, Urien S, Rodgers AH, Ratterree M, Struck RF, Waud WR, Serota DG, Bastian G, Jursic BS, Morgan LR.

Cancer Chemother Pharmacol. 2005 Feb;55(2):143-51. Epub 2004 Sep 14.

PMID:
15592722
29.

SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.

Alley MC, Hollingshead MG, Pacula-Cox CM, Waud WR, Hartley JA, Howard PW, Gregson SJ, Thurston DE, Sausville EA.

Cancer Res. 2004 Sep 15;64(18):6700-6.

30.

Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene.

Hong JS, Waud WR, Levasseur DN, Townes TM, Wen H, McPherson SA, Moore BA, Bebok Z, Allan PW, Secrist JA 3rd, Parker WB, Sorscher EJ.

Cancer Res. 2004 Sep 15;64(18):6610-5.

31.

Purine nucleoside antimetabolites in development for the treatment of cancer.

Parker WB, Secrist JA 3rd, Waud WR.

Curr Opin Investig Drugs. 2004 Jun;5(6):592-6. Review.

PMID:
15242246
32.

Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system.

Bennett EM, Anand R, Allan PW, Hassan AE, Hong JS, Levasseur DN, McPherson DT, Parker WB, Secrist JA 3rd, Sorscher EJ, Townes TM, Waud WR, Ealick SE.

Chem Biol. 2003 Dec;10(12):1173-81.

PMID:
14700625
33.

The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation.

Kraus LA, Samuel SK, Schmid SM, Dykes DJ, Waud WR, Bissery MC.

Invest New Drugs. 2003 Aug;21(3):259-68.

PMID:
14578676
34.

Preclinical antitumor activity of 4'-thio-beta-D-arabinofuranosylcytosine (4'-thio-ara-C).

Waud WR, Gilbert KS, Shepherd RV, Montgomery JA, Secrist JA 3rd.

Cancer Chemother Pharmacol. 2003 May;51(5):422-6. Epub 2003 Apr 1.

PMID:
12679884
35.

A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration.

Gadi VK, Alexander SD, Waud WR, Allan PW, Parker WB, Sorscher EJ.

J Pharmacol Exp Ther. 2003 Mar;304(3):1280-4.

PMID:
12604707
36.

Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase.

Parker WB, Allan PW, Hassan AE, Secrist JA 3rd, Sorscher EJ, Waud WR.

Cancer Gene Ther. 2003 Jan;10(1):23-9.

PMID:
12489025
37.
38.

Synthesis and antitumor activity of several new analogues of penclomedine and its metabolites.

Tiwari A, Riordan JM, Waud WR, Struck RF.

J Med Chem. 2002 Feb 28;45(5):1079-85.

PMID:
11855988
39.

Acyl derivatives of demethylpenclomedine, an antitumor-active, non-neurotoxic metabolites of penclomedine.

Struck RF, Tiwari A, Friedman HS, Keir S, Morgan LR, Waud WR.

Cancer Chemother Pharmacol. 2001 Jul;48(1):47-52.

PMID:
11488524
40.

Synthesis and structure activity relationships of 5-substituted-4'-thio-beta-D-arabinofuranosylcytosines.

Tiwari KN, Shortnacy-Fowler AT, Cappellacci L, Waud WR, Parker WB, Montgomery JA, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2000 Oct-Dec;19(10-12):2005-17.

PMID:
11200287
41.

Metabolism of 4'-thio-beta-D-arabinofuranosylcytosine in CEM cells.

Parker WB, Shaddix SC, Rose LM, Waud WR, Shewach DS, Tiwari KN, Secrist JA 3rd.

Biochem Pharmacol. 2000 Dec 15;60(12):1925-32.

PMID:
11108809
42.

Synthesis and evaluation of several new (2-chloroethyl)nitrosocarbamates as potential anticancer agents.

Reynolds RC, Tiwari A, Harwell JE, Gordon DG, Garrett BD, Gilbert KS, Schmid SM, Waud WR, Struck RF.

J Med Chem. 2000 Apr 20;43(8):1484-8.

PMID:
10780904
43.

Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)adenine (Cl-F-ara-A).

Waud WR, Schmid SM, Montgomery JA, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2000 Jan-Feb;19(1-2):447-60.

PMID:
10772726
44.

Synthesis of 4'-thio-beta-D-arabinofuranosylcytosine (4'-thio-ara-C) and comparison of its anticancer activity with that of ara-C.

Tiwari KN, Shortnacy-Fowler AT, Cappellacci L, Parker WB, Waud WR, Montgomery JA, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2000 Jan-Feb;19(1-2):329-40.

PMID:
10772718
45.

Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts.

Hill BT, Fiebig HH, Waud WR, Poupon MF, Colpaert F, Kruczynski A.

Eur J Cancer. 1999 Mar;35(3):512-20.

PMID:
10448309
46.

Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase.

Secrist JA 3rd, Parker WB, Allan PW, Bennett LL Jr, Waud WR, Truss JW, Fowler AT, Montgomery JA, Ealick SE, Wells AH, Gillespie GY, Gadi VK, Sorscher EJ.

Nucleosides Nucleotides. 1999 Apr-May;18(4-5):745-57.

PMID:
10432677
47.

Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.

Kadhim SA, Bowlin TL, Waud WR, Angers EG, Bibeau L, DeMuys JM, Bednarski K, Cimpoia A, Attardo G.

Cancer Res. 1997 Nov 1;57(21):4803-10.

48.

In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase.

Parker WB, King SA, Allan PW, Bennett LL Jr, Secrist JA 3rd, Montgomery JA, Gilbert KS, Waud WR, Wells AH, Gillespie GY, Sorscher EJ.

Hum Gene Ther. 1997 Sep 20;8(14):1637-44.

PMID:
9322865
49.

Stabilized analogs of thymopentin. 3. Evaluation of ketomethylene pseudopeptides for antiarthritic properties.

Smith RL, Dousman L, Waud WR, DeGraw JI.

J Med Chem. 1997 Jul 18;40(15):2407-11.

PMID:
9240355
50.

Stabilized analogs of thymopentin. 2. 1,2- and 3,4-ketomethylene pseudopeptides.

DeGraw JI, Almquist RG, Hiebert CK, Judd AK, Dousman L, Smith RL, Waud WR, Uchida I.

J Med Chem. 1997 Jul 18;40(15):2398-406.

PMID:
9240354

Supplemental Content

Support Center